{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:29:17Z","timestamp":1760142557838,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.biopha.2004.12.002","type":"journal-article","created":{"date-parts":[[2005,7,12]],"date-time":"2005-07-12T16:13:10Z","timestamp":1121184790000},"page":"524-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of toxicities induced by chemotherapy in breast cancer patients"],"prefix":"10.1016","volume":"59","author":[{"given":"Lubna","family":"Mehreen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziza","family":"Khanam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2004.12.002_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1054\/brst.2002.0418","article-title":"Morbidity of tamoxifen-perceptions of patients and healthcare professionals","volume":"11","author":"Adlard","year":"2002","journal-title":"Breast"},{"key":"10.1016\/j.biopha.2004.12.002_bib2","series-title":"Clinical laboratory method, 8th ed","first-page":"396","author":"Baur","year":"1986"},{"key":"10.1016\/j.biopha.2004.12.002_bib3","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1002\/1097-0142(197706)39:6<2904::AID-CNCR2820390677>3.0.CO;2-8","article-title":"The CMF program for operatable breast cancer with positive axillary nodes","volume":"39","author":"Bonadonna","year":"1997","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2004.12.002_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1179\/joc.2003.15.2.184","article-title":"Randomized, controlled, multicenter phase III trial of standard-dose of flourouracil\u2013epirubicin\u2013cyclophosphamide (FEC) compared with time-intensive FEC (FEC-G) and mitoxantrone\u2013methotrexate mitomycin C (MMMG) in metastatic breast carcinoma","volume":"15","author":"Capotorto","year":"2003","journal-title":"J. Chemother."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2004.12.002_bib5","first-page":"S1","article-title":"Scientific review of tamoxifen over view from medical oncologist","volume":"1","author":"Carlson","year":"1997","journal-title":"Semin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2004.12.002_bib6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2000.18.7.1412","article-title":"Burdens and benefits of adjuvant cyclophosphamide, methotrexate and 5-flouroracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study group Trial VII","volume":"18","author":"Crivellari","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2004.12.002_bib7","first-page":"119","article-title":"Tamoxifen vs. placebo double blind adjuvant trial in elderly women with stage 2 breast cancer","volume":"1","author":"Cunning","year":"1986","journal-title":"NCI Monogr."},{"key":"10.1016\/j.biopha.2004.12.002_bib8","first-page":"765","article-title":"Sternson and Barnett. Clinical pharmacology of tamoxifen in patients with breast cancer. Comparison of traditional and loading dose schedules","volume":"64","author":"Fabian","year":"1986","journal-title":"Cancer Treat. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2004.12.002_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000011948","article-title":"Intensified adjuvant cyclophosphamide, methotrexate and 5-flouroracil therapy: a dose-finding study for ambulatory patients with breast cancer","volume":"56","author":"Hietanen","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.biopha.2004.12.002_bib10","unstructured":"National Nutritional Survey Report. 1988; National Institute of Health, Government of Pakistan."},{"issue":"5","key":"10.1016\/j.biopha.2004.12.002_bib11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00000421-199610000-00014","article-title":"A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone refractory adenocarcinoma of the prostate","volume":"19","author":"Pientka","year":"1996","journal-title":"Am. J. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2004.12.002_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1006\/gyno.1996.0074","article-title":"Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma","volume":"60","author":"Pinelli","year":"1996","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2004.12.002_bib13","first-page":"3357","article-title":"Tamoxifen induce hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague dawley rats","volume":"54","author":"Sargent","year":"1994","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2004.12.002_bib14","first-page":"1581","article-title":"Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma","volume":"15","author":"Wada","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2004.12.002_bib15","series-title":"Treatment of cancer, 2nd ed","first-page":"139","author":"Karol","year":"1990"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332205001204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332205001204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:35:02Z","timestamp":1760092502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332205001204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0753332205001204"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2004.12.002","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of toxicities induced by chemotherapy in breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2004.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}